12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Nivolumab: Phase III started

Bristol-Myers began a double-blind, placebo-controlled, international Phase III trial in about 915 patients to compare IV nivolumab as monotherapy or in combination with IV Yervoy ipilimumab vs. Yervoy alone. Patients will receive 3 mg/kg nivolumab every 2 weeks; concurrent dosing of 1 mg/kg nivolumab plus Yervoy every 3 weeks for 4 doses...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >